182
Views
12
CrossRef citations to date
0
Altmetric
Original Article

Short-term Moderate-dose Pelvic Radiotherapy of Advanced Bladder Carcinoma. A Questionnaire-based Evaluation of its Symptomatic Effect

&
Pages 735-738 | Received 18 Oct 1990, Accepted 20 Feb 1991, Published online: 05 Jul 2013

References

  • Chan RC, Bracken RB, Johnson DE. Single dose whole pelvis megavoltage irradiation for palliative control of hematuria or ureteral obstruction. J Urol 1979; 122: 750–1.
  • Cohen JM, Persky L, Resnick MI. Pattern of urinary symp-toms in patients with metastatic bladder cancer. J Urol 1986; 36: 586–8.
  • Egghart G, Altwein JE. Palliative therapy in cancer of the bladder: experience with 179 patients (Abstract 259). J Urol 1984; 131: 168.
  • Montie JE, Whitmore WF, Grabstald HM, Yagoda A. Unre-sectable carcinoma of the bladder. Cancer 1983; 51: 2351–5.
  • Silber I, Bowles WT, Cordonnier JJ. Palliative treatment of carcinoma of the urinary bladder. Cancer 1969; 23: 586–8.
  • Fossa SD, Splinter T, Roozendaal KJ, et al. members of the EORTC GU Group: A phase 11 study of 4-Epi-Adriamycin in advanced transitional cell cancer. Eur J Cancer Clin Oncol 1989; 25: 389–90.
  • Fossa SD, Sager EM, Hosbach G Wcehre H, Ous S. Cisplatin and medium dose methotrexate in advanced transitional cell carcinoma of the urinary bladder. Scand J Urol Nephrol 1990; 24: 199–204.
  • UICC. TNM classification of malignant tumours. Harmer HH, ed. Third edition, Geneva; 1978: 113–7.
  • Mameghan H, Fisher R. Invasive bladder cancer. Prognostic factors and results of radiotherapy with and without cystec-tomy. Br J Urol 1989; 63: 251–8.
  • Fossa SD, Aaronsen NK, Newling D, et al. Quality of life and treatment of hormone resistant metastatic prostatic cancer. Eur J Cancer 1990; 26: 1133–6.
  • Prout GR, Marshall VF. The prognosis with untreated blad-der tumors. Cancer 1956; 9: 551–8.
  • Shipley WU, Rose MA. Bladder cancer. Cancer 1985; 55: 2278–84.
  • Rugg T, Lartigau E, Saunders MI, Dische S. Accelerated radiotherapy and morbidity (Abstract). 5th European Confer-ence on Clinical oncology, London 3–7 Sept 1989.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.